Clinical data | |
---|---|
Trade names | Abasol |
Routes of administration | Topical (cream) |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
ChEBI | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.125.129 |
Chemical and physical data | |
Formula | C21H22N4OS |
Molar mass | 378.49 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Abafungin (INN) is a broad-spectrum antifungal agent with a novel mechanism of action for the treatment of dermatomycoses.
Abasol is a topical cream formulation of abafungin by York Pharma.[1]
Abafungin was first synthesized at Bayer AG, Leverkusen, Germany. A study of H2-antagonists related to famotidine, resulted in the discovery of its antifungal properties.[2]
Its development seems to have been discontinued in 2009.[3]
Unlike imidazole- and triazole-class antifungals, abafungin directly impairs the fungal cell membrane.[2]
In addition, abafungin inhibits the enzyme sterol 24-C-methyltransferase, modifying the composition of the fungal membrane.[4]
Abafungin has antibiotic activity against gram-positive bacteria as well as sporicidal activity.[5]
Wall/ membrane |
| ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular |
| ||||||||||||||||||||||
Others | |||||||||||||||||||||||
|